



|  |                   |    |   |                          |   |
|--|-------------------|----|---|--------------------------|---|
| <b>FIRST SUPPLEMENTAL<br/>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br>(Use as many sheets as necessary) |                   |    |   | <b>Complete if Known</b> |   |
|  |                   |    |   | Application Number       | 10/553,685 (Nat'l. Phase of<br>PCT/US2004/008323) |
|  |                   |    |   | Filing Date              | §371 Date: November 1, 2006                       |
|  |                   |    |   | First Named Inventor     | MI, Sha   |
|  |                   |    |   | Art Unit                 | 1656  |
| Examiner Name  | CARLSON, Karen C. |    |   |                          |   |
| Sheet  | 1                 | of | 5 | Attorney Docket Number   | 2159.0440003/EJH/CLD                              |

| U.S. PATENT DOCUMENTS |                          |  |                                |  |   |
|-----------------------|--------------------------|--|--------------------------------|--|---|
| Examiner<br>Initials* | Cite<br>No. <sup>1</sup> | Document Number                          | Publication Date<br>MM-DD-YYYY | Name of Patentee or<br>Applicant of Cited Document | Pages, Columns, Lines,<br>Where Relevant Passages<br>or Relevant Figures Appear |
|                       |                          | Number-Kind Code <sup>2</sup> (if Known) |                                |  |   |
|                       | US22                     | 4,444,887                                | 04-24-1984                     | Michael K. Hoffman                                 |   |
|                       | US23                     | 4,694,778                                | 09-22-1987                     | Learn <i>et al.</i>                                |   |
|                       | US24                     | 4,716,111                                | 12-29-1987                     | Osband <i>et al.</i>                               |   |
|                       | US25                     | 4,816,397                                | 03-28-1989                     | Boss <i>et al.</i>                                 |   |
|                       | US26                     | 4,816,567                                | 03-28-1989                     | Cabilly <i>et al.</i>                              |   |
|                       | US27                     | 4,946,778                                | 08-07-1990                     | Ladner <i>et al.</i>                               |   |
|                       | US28                     | 5,122,464                                | 06-16-1992                     | Wilson <i>et al.</i>                               |   |
|                       | US29                     | 5,223,409                                | 06-29-1993                     | Ladner <i>et al.</i>                               |   |
|                       | US30                     | 5,225,539                                | 07-06-1993                     | Gregory P. Winter                                  |   |
|                       | US31                     | 5,258,498                                | 11-02-1993                     | Huston <i>et al.</i>                               |   |
|                       | US32                     | 5,314,995                                | 05-24-1997                     | Fell, Jr., <i>et al.</i>                           |   |
|                       | US33                     | 5,403,484                                | 04-04-1995                     | Ladner <i>et al.</i>                               |   |
|                       | US34                     | 5,413,923                                | 05-09-1995                     | Kucherlapati <i>et al.</i>                         |   |
|                       | US35                     | 5,427,908                                | 06-27-1995                     | Dower <i>et al.</i>                                |   |
|                       | US36                     | 5,516,637                                | 05-14-1996                     | Huang <i>et al.</i>                                |   |
|                       | US37                     | 5,530,101                                | 06-25-1996                     | Queen <i>et al.</i>                                |   |
|                       | US38                     | 5,545,806                                | 08-13-1996                     | Lonberg <i>et al.</i>                              |   |
|                       | US39                     | 5,565,332                                | 10-15-1996                     | Hoogenboom <i>et al.</i>                           |   |
|                       | US40                     | 5,569,825                                | 10-29-1996                     | Lonberg <i>et al.</i>                              |   |
|                       | US41                     | 5,571,698                                | 11-05-1996                     | Ladner <i>et al.</i>                               |   |

| FOREIGN PATENT DOCUMENTS |                          |   |                                |  |                |
|--------------------------|--------------------------|---|--------------------------------|--|----------------|
| Examiner<br>Initials*    | Cite<br>No. <sup>1</sup> | Foreign Patent Document   | Publication Date<br>MM-DD-YYYY | Name of Patentee or<br>Applicant of Cited Document | T <sup>6</sup> |
|                          |                          | Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known) |                                |  |                |
|                          | FP24                     | WO 88/09810 A1  | 12-15-1988                     | Synthetic Genetics                                 |                |
|                          | FP25                     | WO 89/01036 A1  | 02-09-1989                     | Celltech Limited                                   |                |
|                          | FP26                     | WO 89/10134 A1  | 11-02-1989                     | The Regents of the Univ. of CA                     |                |
|                          | FP27                     | WO 89/12624 A2  | 12-28-1989                     | Cetus Corporation                                  |                |
|                          | FP28                     | WO 90/02809 A1  | 03-22-1990                     | Protein Engineering Corp.                          |                |
|                          | FP29                     | WO 90/11364 A1  | 10-04-1990                     | University Patents, Inc.                           |                |
|                          | FP30                     | WO 91/09967 A1  | 07-11-1991                     | Celltech Limited                                   |                |
|                          | FP31                     | WO 91/10737 A1  | 07-25-1991                     | Molecular Affinities Corp.                         |                |
|                          | FP32                     | WO 91/10741 A1  | 07-25-1991                     | Cell Genesys, Inc.                                 |                |
|                          | FP33                     | WO 91/14438 A1  | 10-03-1991                     | Trustees of Columbia Univ. in the City of NY       |                |
|                          | FP34                     | WO 92/01047 A1  | 01-23-1992                     | Cambridge Antibody Tech., Ltd.                     |                |

|                       |                    |
|-----------------------|--------------------|
| Examiner<br>Signature | Date<br>Considered |
|-----------------------|--------------------|

846353\_1.DOC

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \*Applicant's unique citation designation number (optional). \*See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. \*Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \*For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \*Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. \*Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

|   |   |    |   |                          |  |
|---|---|----|---|--------------------------|--|
| Substitute for form 1449/PTO<br><br><b>FIRST SUPPLEMENTAL<br/>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><i>(Use as many sheets as necessary)</i> |   |    |   | <b>Complete if Known</b> |  |
|   |   |    |   | Application Number       | 10/553,685 ( <i>Natl. Phase of PCT/US2004/008323</i> ) |
|   |   |    |   | Filing Date              | §371 Date: November 1, 2006                            |
|   |   |    |   | First Named Inventor     | MI, Sha  |
|   |   |    |   | Art Unit                 | 1656   |
|   |   |    |   | Examiner Name            | CARLSON, Karen C.                                      |
| Sheet   | 2 | of | 5 | Attorney Docket Number   | 2159.0440003/EJH/CLD                                   |

| U.S. PATENT DOCUMENTS |                       |  |                                |  |   |
|-----------------------|-----------------------|--|--------------------------------|--|---|
| Examiner Initials*    | Cite No. <sup>1</sup> | Document Number                          | Publication Date<br>MM-DD-YYYY | Name of Patentee or<br>Applicant of Cited Document | Pages, Columns, Lines,<br>Where Relevant Passages<br>or Relevant Figures Appear |
|                       |                       | Number-Kind Code <sup>2</sup> (if known) |                                |  |   |
|                       | US42                  | 5,574,009                                | 11-12-1996                     | Cohen <i>et al.</i>                                |   |
|                       | US43                  | 5,580,717                                | 12-03-1996                     | Dower <i>et al.</i>                                |   |
|                       | US44                  | 5,585,089                                | 12-17-1996                     | Queen <i>et al.</i>                                |   |
|                       | US45                  | 5,589,369                                | 12-31-1996                     | Seidman <i>et al.</i>                              |   |
|                       | US46                  | 5,625,126                                | 04-29-1997                     | Lonberg <i>et al.</i>                              |   |
|                       | US47                  | 5,633,425                                | 05-27-1997                     | Lonberg <i>et al.</i>                              |   |
|                       | US48                  | 5,658,570                                | 08-19-1997                     | Newman <i>et al.</i>                               |   |
|                       | US49                  | 5,658,727                                | 08-19-1997                     | Barbas <i>et al.</i>                               |   |
|                       | US50                  | 5,661,016                                | 08-26-1997                     | Lonberg <i>et al.</i>                              |   |
|                       | US51                  | 5,693,761                                | 12-02-1997                     | Queen <i>et al.</i>                                |   |
|                       | US52                  | 5,693,762                                | 12-02-1997                     | Queen <i>et al.</i>                                |   |
|                       | US53                  | 5,693,780                                | 12-02-1997                     | Newman <i>et al.</i>                               |   |
|                       | US54                  | 5,698,426                                | 12-16-1997                     | William D. Huse                                    |   |
|                       | US55                  | 5,725,859                                | 03-10-1998                     | Omer   |   |
|                       | US56                  | 5,733,743                                | 03-31-1998                     | Johnson <i>et al.</i>                              |   |
|                       | US57                  | 5,750,753                                | 05-12-1998                     | Kimae <i>et al.</i>                                |   |
|                       | US58                  | 5,756,096                                | 05-26-1998                     | Newman <i>et al.</i>                               |   |
|                       | US59                  | 5,772,997                                | 06-30-1998                     | Hudziak <i>et al.</i>                              |   |
|                       | US60                  | 5,780,225                                | 07-14-1998                     | Wigler <i>et al.</i>                               |   |
|                       | US61                  | 5,807,715                                | 09-15-1998                     | Morrison <i>et al.</i>                             |   |
|                       | US62                  | 5,811,524                                | 09-22-1998                     | Brams <i>et al.</i>                                |   |

| FOREIGN PATENT DOCUMENTS |                       |  |                                |  |                |
|--------------------------|-----------------------|--|--------------------------------|--|----------------|
| Examiner Initials*       | Cite No. <sup>1</sup> | Foreign Patent Document  | Publication Date<br>MM-DD-YYYY | Name of Patentee or<br>Applicant of Cited Document           | T <sup>6</sup> |
|                          |                       | Country Code <sup>3</sup> Number <sup>4</sup><br>Kind Code <sup>5</sup> (if known) |                                |  |                |
|                          | FP35                  | WO 92/08495 A1   | 05-29-1992                     | Abbott Biotech, Inc.   |                |
|                          | FP36                  | WO 92/18619 A1   | 10-29-1992                     | The Scripps Research Inst.                                   |                |
|                          | FP37                  | EP 0 519 596 A1  | 12-23-1992                     | Merck & Co. Inc.   |                |
|                          | FP38                  | WO 92/22324 A1   | 12-23-1992                     | Xoma Corporation   |                |
|                          | FP39                  | WO 93/11236 A1   | 06-10-1993                     | Medical Research Council; Cambridge Antibody Technology Ltd. |                |
|                          | FP40                  | EP 0 396 387 B1  | 12-22-1993                     | Research Development Foundation                              |                |
|                          | FP41                  | EP 0 368 684 B1  | 03-09-1994                     | Medical Research Council                                     |                |
|                          | FP42                  | WO 94/09817 A1   | 05-11-1994                     | City of Hope   |                |
|                          | FP43                  | EP 0 239 400 B1  | 08-03-1994                     | Medical Research Council                                     |                |

|                    |                 |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
|--------------------|-----------------|

846353\_1.DOC

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \*Applicant's unique citation designation number (optional). \* See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. \* Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \* For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \* Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. \* Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

|   |   |    |   |                          |  |
|---|---|----|---|--------------------------|--|
| Substitute for form 1449/PTO<br><br><b>FIRST SUPPLEMENTAL<br/>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><i>(Use as many sheets as necessary)</i> |   |    |   | <b>Complete if Known</b> |  |
|   |   |    |   | Application Number       | 10/553,685 ( <i>Natl. Phase of PCT/US2004/008323</i> ) |
|   |   |    |   | Filing Date              | §371 Date: November 1, 2006                            |
|   |   |    |   | First Named Inventor     | MI, Sha  |
|   |   |    |   | Art Unit                 | 1656   |
|   |   |    |   | Examiner Name            | CARLSON, Karen C.                                      |
| Sheet   | 3 | of | 5 | Attorney Docket Number   | 2159.0440003/EJH/CLD                                   |

| U.S. PATENT DOCUMENTS |                       |  |                                |  |   |
|-----------------------|-----------------------|--|--------------------------------|--|---|
| Examiner Initials*    | Cite No. <sup>1</sup> | Document Number                          | Publication Date<br>MM-DD-YYYY | Name of Patentee or<br>Applicant of Cited Document | Pages, Columns, Lines,<br>Where Relevant Passages<br>or Relevant Figures Appear |
|                       |                       | Number-Kind Code <sup>2</sup> (if known) |                                |  |   |
|                       | US63                  | 5,814,318                                | 09-29-1998                     | Lonberg <i>et al.</i>                              |   |
|                       | US64                  | 5,821,047                                | 10-13-1998                     | Garrard <i>et al.</i>                              |   |
|                       | US65                  | 5,837,821                                | 11-17-1998                     | Anna M. Wu   |   |
|                       | US66                  | 5,892,019                                | 04-06-1999                     | Schlom <i>et al.</i>                               |   |
|                       | US67                  | 5,914,237                                | 06-22-1999                     | Godowski <i>et al.</i>                             |   |
|                       | US68                  | 5,939,598                                | 08-17-1999                     | Kucherlapati <i>et al.</i>                         |   |
|                       | US69                  | 5,969,108                                | 10-19-1999                     | McCafferty <i>et al.</i>                           |   |
|                       | US70                  | 6,025,145                                | 02-15-2000                     | Godowski <i>et al.</i>                             |   |
|                       | US71                  | 6,054,561                                | 04-25-2000                     | Ring   |   |
|                       | US72                  | 6,075,181                                | 06-13-2000                     | Kucherlapati <i>et al.</i>                         |   |
|                       | US73                  | 6,150,584                                | 11-21-2000                     | Kucherlapati <i>et al.</i>                         |   |
|                       | US74                  | 6,159,730                                | 12-12-2000                     | Mitchell E. Reff                                   |   |
|                       | US75                  | 6,180,370 B1                             | 10-30-2001                     | Queen <i>et al.</i>                                |   |
|                       | US76                  | 6,280,964 B1                             | 08-28-2001                     | Kavanaugh <i>et al.</i>                            |   |
|                       | US77                  | 6,333,169 B1                             | 12-25-2001                     | Hudziak <i>et al.</i>                              |   |
|                       | US78                  | 6,387,371 B1                             | 05-14-2002                     | Hudziak <i>et al.</i>                              |   |
|                       | US79                  | 6,399,063 B1                             | 06-04-2002                     | Hudziak <i>et al.</i>                              |   |
|                       | US80                  | 6,413,777 B1                             | 07-02-2002                     | Reff <i>et al.</i>                                 |   |
|                       | US81                  | 6,420,140 B1                             | 07-16-2002                     | Hori <i>et al.</i>                                 |   |
|                       | US82                  | 6,458,592 B1                             | 10-01-2002                     | Jakobovits <i>et al.</i>                           |   |
|                       | US83                  | 6,696,290 B2                             | 02-24-2004                     | Fitzpatrick <i>et al.</i>                          |   |

| FOREIGN PATENT DOCUMENTS |                       |  |                                |  |                |
|--------------------------|-----------------------|--|--------------------------------|--|----------------|
| Examiner Initials*       | Cite No. <sup>1</sup> | Foreign Patent Document  | Publication Date<br>MM-DD-YYYY | Name of Patentee or<br>Applicant of Cited Document | T <sup>6</sup> |
|                          |                       | Country Code <sup>3</sup> Number <sup>4</sup><br>Kind Code <sup>5</sup> (if known) |                                |  |                |
|                          | FP44                  | WO 95/15982 A2   | 06-15-1995                     | Genzyme Corporation                                |                |
|                          | FP45                  | WO 95/20401 A1   | 08-03-1995                     | Trustees of Boston Univ.                           |                |
|                          | FP46                  | EP 0 401 384 B1  | 03-13-1996                     | Kirin-Amgen Inc.                                   |                |
|                          | FP47                  | WO 96/33735 A1   | 10-31-1996                     | Cell Genesys, Inc.                                 |                |
|                          | FP48                  | WO 96/34096 A1   | 10-31-1996                     | Cell Genesys, Inc.                                 |                |
|                          | FP49                  | WO 97/00271 A1   | 01-03-1997                     | The Regents of the University of California        |                |
|                          | FP50                  | WO 98/16654 A1   | 04-23-1998                     | Japan Tobacco, Inc.; Abgenix, Inc.                 |                |
|                          | FP51                  | WO 98/24893 A2   | 06-11-1998                     | Abgenix, Inc.                                      |                |
|                          | FP52                  | WO 98/46645 A2   | 10-22-1998                     | Peter KUFER  |                |

|                    |                 |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
|--------------------|-----------------|

846353\_1.DOC

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \*Applicant's unique citation designation number (optional). \*See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. \*Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \*For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \*Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. \*Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

|   |   |    |   |                          |  |
|---|---|----|---|--------------------------|--|
| Substitute for form 1449/PTO<br><br><b>FIRST SUPPLEMENTAL<br/>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><i>(Use as many sheets as necessary)</i> |   |    |   | <b>Complete if Known</b> |  |
|   |   |    |   | Application Number       | 10/553,685 ( <i>Natl. Phase of PCT/US2004/008323</i> ) |
|   |   |    |   | Filing Date              | §371 Date: November 1, 2006                            |
|   |   |    |   | First Named Inventor     | MI, Sha  |
|   |   |    |   | Art Unit                 | 1656   |
|   |   |    |   | Examiner Name            | CARLSON, Karen C.                                      |
| Sheet   | 4 | of | 5 | Attorney Docket Number   | 2159.0440003/EJH/CLD                                   |

| U.S. PATENT DOCUMENTS |                       |  |                                |  |   |
|-----------------------|-----------------------|--|--------------------------------|--|---|
| Examiner Initials*    | Cite No. <sup>1</sup> | Document Number                          | Publication Date<br>MM-DD-YYYY | Name of Patentee or<br>Applicant of Cited Document | Pages, Columns, Lines,<br>Where Relevant Passages<br>or Relevant Figures Appear |
|                       |                       | Number-Kind Code <sup>2</sup> (If Known) |                                |  |   |
|                       | US84                  | 6,949,245 B1                             | 09-27-2005                     | Sliwkowski   |   |
|                       | US85                  | 6,987,088 B1                             | 01-17-2006                     | Dennis   |   |
|                       | US86                  | 7,098,302 B1                             | 08-29-2006                     | Krag <i>et al.</i>                                 |   |
|                       | US87                  | 7,223,558 B1                             | 05-29-2007                     | Wu <i>et al.</i>                                   |   |
|                       | US88                  | 2002/0004587 A1                          | 01-10-2002                     | Miller <i>et al.</i>                               |   |
|                       | US89                  | 2002/0182671 A1                          | 12-05-2002                     | Lal Preeti <i>et al.</i>                           |   |
|                       | US90                  | 2004/0005579 A1                          | 01-08-2004                     | Birse <i>et al.</i>                                |   |
|                       | US91                  | 2005/0153396 A1                          | 07-14-2005                     | Baker <i>et al.</i>                                |   |
|                       | US92                  | 2006/0034840 A1                          | 02-16-2006                     | Agus <i>et al.</i>                                 |   |
|                       | US93                  | 2006/0088523 A1                          | 04-27-2006                     | Andya <i>et al.</i>                                |   |
|                       | US94                  | 2007/0071675 A1                          | 03-29-2007                     | Wu <i>et al.</i>                                   |   |
|                       | US95                  | 2007/0083334 A1                          | 04-12-2007                     | Mintz <i>et al.</i>                                |   |
|                       | US96                  | 2007/0105122 A1                          | 05-10-2007                     | Ota <i>et al.</i>                                  |   |
|                       | US97                  | 2007/0274918 A1                          | 11-29-2007                     | Mosyak <i>et al.</i>                               |   |
|                       |                       |  |                                |  |   |
|                       |                       |  |                                |  |   |
|                       |                       |  |                                |  |   |
|                       |                       |  |                                |  |   |
|                       |                       |  |                                |  |   |
|                       |                       |  |                                |  |   |
|                       |                       |  |                                |  |   |
|                       |                       |  |                                |  |   |

| FOREIGN PATENT DOCUMENTS |                       |  |                                |  |                |
|--------------------------|-----------------------|--|--------------------------------|--|----------------|
| Examiner Initials*       | Cite No. <sup>1</sup> | Foreign Patent Document  | Publication Date<br>MM-DD-YYYY | Name of Patentee or<br>Applicant of Cited Document | T <sup>6</sup> |
|                          |                       | Country Code <sup>3</sup> Number <sup>4</sup><br>Kind Code <sup>5</sup> (if known) |                                |  |                |
|                          | FP53                  | WO 98/050433 A2  | 11-12-1998                     | Abgenix, Inc.                                      |                |
|                          | FP54                  | WO 98/52976 A1   | 11-26-1998                     | Biovation Limited                                  |                |
|                          | FP55                  | WO 00/34317 A2   | 06-15-2000                     | Biovation Ltd.                                     |                |
|                          | FP56                  | WO 00/58473 A2   | 10-05-2000                     | Curagen Corp.                                      |                |
|                          | FP57                  | WO 01/055333 A2  | 08-02-2001                     | Hyseq Inc.   |                |
|                          | FP58                  | WO 01/55317 A2   | 08-02-2001                     | Human Genome Sciences Inc.                         |                |
|                          | FP59                  | WO 01/59063 A2   | 08-16-2001                     | Human Genome Sciences Inc.                         |                |
|                          | FP60                  | WO 02/060955 A2  | 08-08-2002                     | IDEC Pharmaceuticals Corp.                         |                |
|                          | FP61                  | WO 02/096948 A2  | 12-05-2002                     | IDEC Pharmaceuticals Corp.                         |                |
|                          | FP62                  | EP 0 058 481 B2  | 05-21-2003                     | Astra Zeneca AB                                    |                |
|                          | FP63                  | WO 03/061559 A2  | 07-31-2003                     | University of Vermont and State Agricultural       |                |

|                    |                 |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
|--------------------|-----------------|

846353\_1.DOC

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \*Applicant's unique citation designation number (optional). \* See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. \* Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \* For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \* Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. \* Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

[illegible][illegible]

846353v1

|                       |  |                    |  |
|-----------------------|--|--------------------|--|
| Examiner<br>Signature |  | Date<br>Considered |  |
|-----------------------|--|--------------------|--|

846353 1.DOC

846353\_1.DOC

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \*Applicant's unique citation designation number (optional). \* See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. \* Enter Office that issued the document, by the two-letter code (WIPO Standard 2.3). \* For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \* Kind of document by the appropriate symbols as indicated on the document under WIPO Standard 2.16 if possible. \* Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

*If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.*

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|  |   |    |   |                          |  |
|--|---|----|---|--------------------------|--|
| <b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><i>(Use as many sheets as necessary)</i> |   |    |   | <b>Complete if Known</b> |  |
|  |   |    |   | Application Number       | 10/553,685 ( <i>Natl. Phase of PCT/US2004/008323</i> ) |
|  |   |    |   | Filing Date              | §371 Date: November 1, 2006                            |
|  |   |    |   | First Named Inventor     | MI, Sha  |
|  |   |    |   | Art Unit                 | 1656   |
|  |   |    |   | Examiner Name            | CARLSON, Karen C.                                      |
| Sheet  | 1 | of | 7 | Attorney Docket Number   | 2159.0440003/EJH/CLD                                   |

| NON PATENT LITERATURE DOCUMENTS |                       |  |                |
|---------------------------------|-----------------------|--|----------------|
| Examiner Initials*              | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published     | T <sup>2</sup> |
|                                 | NPL33                 | Battaglia, G., <i>et al.</i> , "Protective role of group-II metabotropic glutamate receptors against nigro-striatal degeneration induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice," <i>Neuropharmacol.</i> 45:155-166, Elsevier Science Ltd. (2003) |                |
|                                 | NPL34                 | Baulida, J., <i>et al.</i> , "All ErbB Receptors Other Than the Epidermal Growth Factor Receptor Are Endocytosis Impaired," <i>J. Biol. Chem.</i> 271:5251-5257, The American Society for Biochemistry and Molecular Biology, Inc. (1996)                          |                |
|                                 | NPL35                 | Baulida, J. and Carpenter, G., "Heregulin Degradation in the Absence of Rapid Receptor-Mediated Internalization," <i>Exp. Cell Res.</i> 232:167-172, Academic Press (1997)   |                |
|                                 | NPL36                 | Baumann, N., <i>et al.</i> , "Biology of Oligodendrocyte and Myelin in the Mammalian Central Nervous System," <i>J. Physiol. Rev.</i> 81:871-927, American Physiological Society (2001)  |                |
|                                 | NPL37                 | Blum, M., "A null mutation in TGF- $\alpha$ leads to a reduction in midbrain dopaminergic neurons in the substantia nigra," <i>Nat. Neurosci.</i> 1:374-377, Nature Publishing Group (1998)  |                |
|                                 | NPL38                 | Brundin, P., <i>et al.</i> , "The rotating 6-hydroxydopamine-lesioned mouse as a model for assessing functional effects of neuronal grafting," <i>Brain Res.</i> 366:346-349, Elsevier Publishers B.V. (1986)  |                |
|                                 | NPL39                 | Chang, A., <i>et al.</i> , "Premyelinating Oligodendrocytes in Chronic Lesions of Multiple Sclerosis," <i>N. Engl. J. Med.</i> 346:165-173, Massachusetts Medical Society (2002)   |                |
|                                 | NPL40                 | Citri, A., <i>et al.</i> , "The deaf and the dumb: The biology of ErbB-2 and ErbB-3," <i>Exp. Cell Res.</i> 284:54-65, Elsevier Science (2003)   |                |
|                                 | NPL41                 | Cohen, S., <i>et al.</i> , "Nonchromosomal Antibiotic Resistance in Bacteria: Genetic Transformation of <i>Escherichia coli</i> by R-Factor DNA," <i>Proc. Natl. Acad. Sci. USA</i> 69:2110-2114 (1972)  |                |
|                                 | NPL42                 | Csordás, G., <i>et al.</i> , "Sustained Down-regulation of the Epidermal Growth Factor Receptor by Decorin," <i>J. Biol. Chem.</i> 275:32879-32887, The American Society for Biochemistry and Molecular Biology, Inc. (2000)                                       |                |

|                    |                 |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
|--------------------|-----------------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|   |   |    |   |                          |   |
|---|---|----|---|--------------------------|---|
| Substitute for form 1449/PTO  |   |    |   | <b>Complete if Known</b> |   |
| <b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br>(Use as many sheets as necessary) |   |    |   | Application Number       | 10/553,685 (Natl. Phase of PCT/US2004/008323) |
|   |   |    |   | Filing Date              | §371 Date: November 1, 2006                   |
|   |   |    |   | First Named Inventor     | MI, Sha                                       |
|   |   |    |   | Art Unit                 | 1656  |
|   |   |    |   | Examiner Name            | CARLSON, Karen C.                             |
| Sheet   | 2 | of | 7 | Attorney Docket Number   | 2159.0440003/EJH/CLD                          |

| NON PATENT LITERATURE DOCUMENTS |                       |  |                 |
|---------------------------------|-----------------------|--|-----------------|
| Examiner Initials*              | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published  | T<br>2          |
|                                 | NPL43                 | Eby, M.T., <i>et al.</i> , "TAJ, a Novel Member of the Tumor Necrosis Factor Receptor Family, Activates the c-Jun N-terminal Kinase Pathway and Mediates Caspase-independent Cell Death," <i>J. Biol. Chem.</i> 275:15336-15342, The American Society for Biochemistry and Molecular Biology, Inc. (2000)                      |                 |
|                                 | NPL44                 | Fendly, B.M., <i>et al.</i> , "The Extracellular Domain of HER2/neu Is a Potential Immunogen for Active Specific Immunotherapy of Breast Cancer," <i>J. Biol. Resp. Mod.</i> 9:449-455, Raven Press Ltd. (1990)  |                 |
|                                 | NPL45                 | Fu, Q.-L., <i>et al.</i> , "Blocking LINGO-1 Function Promotes Retinal Ganglion Cell Survival Following Ocular Hypertension and Optic Nerve Transection," <i>Invest. Ophthalm. Vis. Sci.</i> 49:975-985, Association for Research in Vision and Ophthalmology (March 2008)   |                 |
|                                 | NPL46                 | Fuxe, K. and Ungerstedt, U., "Antiparkinsonian Drugs and Dopaminergic Neostriatal Mechanisms: Studies in Rats with Unilateral 6-Hydroxydopamine (=6-OH-DA)-Induced Degeneration of the Nigro-Neostriatal DA Pathway and Quantitative Recording of Rotational Behaviour," <i>Pharmac. Ther. B</i> :41-47, Pergamon Press (1976) |                 |
|                                 | NPL47                 | Ghiglione, C., <i>et al.</i> , "The Transmembrane Molecule Kekkon 1 Acts in a Feedback Loop to Negatively Regulate the Activity of the <i>Drosophila</i> EGF Receptor during Oogenesis," <i>Cell</i> 96:847-856, Cell Press (1999)   |                 |
|                                 | NPL48                 | Gill, S.S., <i>et al.</i> , "Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease," <i>Nat. Med.</i> 9:589-595, Nature Publishing Company (2003)  |                 |
|                                 | NPL49                 | Gill, S.S., <i>et al.</i> , "Addendum: Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease," <i>Nat. Med.</i> 12:479, Nature Publishing Company (April 2006)   |                 |
|                                 | NPL50                 | Gille, G., <i>et al.</i> , "Oxidative Stress to Dopaminergic Neurons as Models of Parkinson's Disease," <i>Ann. N.Y. Acad. Sci.</i> 1018:533-540, New York Academy of Sciences (June 2004)   |                 |
|                                 | NPL51                 | Gur, G., <i>et al.</i> , "LRIG1 restricts growth factor signaling by enhancing receptor ubiquitylation and degradation," <i>EMBO J.</i> 23:3270-3281, Oxford University Press (August 2004)  |                 |
|                                 | NPL52                 | Ha, H., <i>et al.</i> , "Membrane Rafts Play a Crucial Role in Receptor Activator of Nuclear Factor $\kappa$ B Signaling and Osteoclast Function," <i>J. Biol. Chem.</i> 278:18573-18580, The American Society for Biochemistry and Molecular Biology, Inc. (2003)   |                 |
| Examiner Signature              |                       |  | Date Considered |

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|  |   |    |   |                          |  |
|--|---|----|---|--------------------------|--|
| Substitute for form 1449/PTO<br><br><b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><i>(Use as many sheets as necessary)</i> |   |    |   | <b>Complete if Known</b> |  |
|  |   |    |   | Application Number       | 10/553,685 ( <i>Natl. Phase of PCT/US2004/008323</i> ) |
|  |   |    |   | Filing Date              | §371 Date: November 1, 2006                            |
|  |   |    |   | First Named Inventor     | MI, Sha  |
|  |   |    |   | Art Unit                 | 1656   |
|  |   |    |   | Examiner Name            | CARLSON, Karen C.                                      |
| Sheet  | 3 | of | 7 | Attorney Docket Number   | 2159.0440003/EJH/CLD                                   |

| NON PATENT LITERATURE DOCUMENTS |                       |  |                 |
|---------------------------------|-----------------------|--|-----------------|
| Examiner Initials*              | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published  | T <sup>2</sup>  |
|                                 | NPL53                 | Harwerth, I.-M., <i>et al.</i> , "Monoclonal Antibodies against the Extracellular Domain of the erbB-2 Receptor Function as Partial Ligand Agonists," <i>J. Biol. Chem.</i> 267:15160-15167, The American Society for Biochemistry and Molecular Biology, Inc. (1992)                                      |                 |
|                                 | NPL54                 | Hoet, R.M., <i>et al.</i> , "Generation of high-affinity human antibodies by combining donor-derived and synthetic complementarity-determining-region diversity," <i>Nat. Biotechnol.</i> 23:344-348, Nature America Publishing (March 2005)   |                 |
|                                 | NPL55                 | Isacson, O., "Problems and Solutions for Circuits and Synapses in Parkinson's Disease," <i>Neuron</i> 43:165-168, Cell Press (July 2004)   |                 |
|                                 | NPL56                 | Kim, J.Y., <i>et al.</i> , "The Role of ErbB2 Signaling in the Onset of Terminal Differentiation of Oligodendrocytes <i>In Vivo</i> ," <i>J. Neurosci.</i> 23:5561-5571, Society of Neuroscience (2003)  |                 |
|                                 | NPL57                 | Klapper, L.N., <i>et al.</i> , "A subclass of tumor-inhibitory monoclonal antibodies to ErbB-2/HER2 blocks crosstalk with growth factor receptors," <i>Oncogene</i> 14:2099-2109, Nature Publishing Company (1997)   |                 |
|                                 | NPL58                 | Knappik, A., <i>et al.</i> , "Fully Synthetic Human Combinatorial Antibody Libraries (HuCAL) Based on Modular Consensus Frameworks and CDRs Randomized with Trinucleotides," <i>J. Mol. Biol.</i> 296:57-86, Academic Press (2000)   |                 |
|                                 | NPL59                 | Kolodny, E.H., "Dysmyelinating and demyelinating conditions in infancy," <i>Curr. Opin. Neurol. Neurosurg.</i> 6:379-386, Current Science (1993)   |                 |
|                                 | NPL60                 | Kornilova, E., <i>et al.</i> , "Lysosomal Targeting of Epidermal Growth Factor Receptors via a Kinase-dependent Pathway Is Mediated by the Receptor Carboxyl-terminal Residues 1022-1123," <i>J. Biol. Chem.</i> 271:30340-30346, The American Society for Biochemistry and Molecular Biology, Inc. (1996) |                 |
|                                 | NPL61                 | Laederich, M.B., <i>et al.</i> , "The Leucine-rich Repeat Protein LRIG1 Is a Negative Regulator of ErbB Family Receptor Tyrosine Kinases," <i>J. Biol. Chem.</i> 279:47050-47056, The American Society for Biochemistry and Molecular Biology, Inc. (November 2004)  |                 |
|                                 | NPL62                 | Laederich, M.B., <i>et al.</i> , "The Leucine-rich Repeat Protein LRIG1 Is a Negative Regulator of ErbB Family Receptor Tyrosine Kinases," <i>J. Biol. Chem.</i> 279:52806, The American Society for Biochemistry and Molecular Biology, Inc. (December 2004)  |                 |
| Examiner Signature              |                       |  | Date Considered |

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|   |   |    |   |                          |   |
|---|---|----|---|--------------------------|---|
| Substitute for form 1449/PTO  |   |    |   | <b>Complete if Known</b> |   |
| <b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br>(Use as many sheets as necessary) |   |    |   | Application Number       | 10/553,685 (Natl. Phase of PCT/US2004/008323) |
|   |   |    |   | Filing Date              | §371 Date: November 1, 2006                   |
|   |   |    |   | First Named Inventor     | MI, Sha                                       |
|   |   |    |   | Art Unit                 | 1656  |
|   |   |    |   | Examiner Name            | CARLSON, Karen C.                             |
| Sheet   | 4 | of | 7 | Attorney Docket Number   | 2159.0440003/EJH/CLD                          |

| NON PATENT LITERATURE DOCUMENTS |                       |  |                |
|---------------------------------|-----------------------|--|----------------|
| Examiner Initials*              | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published                                      | T <sup>2</sup> |
|                                 | NPL63                 | Li, S., <i>et al.</i> , "Blockade of Nogo-66, Myelin-Associated Glycoprotein, and Oligodendrocyte Myelin Glycoprotein by Soluble Nogo-66 Receptor Promotes Axonal Sprouting and Recovery after Spinal Injury," <i>J. Neurosci.</i> 24:10511-10520, Society of Neuroscience (November 2004) |                |
|                                 | NPL64                 | Lin, L., <i>et al.</i> , "Netrin-1 and slit-2 regulate and direct neurite growth of ventral midbrain dopaminergic neurons," <i>Molec. Cell. Neurosci.</i> 28:547-555, Elsevier Inc. (March 2005)   |                |
|                                 | NPL65                 | Ma, L., <i>et al.</i> , "Ligand-Dependent Recruitment of the ErbB4 Signaling Complex into Neuronal Lipid Rafts," <i>J. Neurosci.</i> 23:3164-3175, Society of Neuroscience (2003)  |                |
|                                 | NPL66                 | Messier, C., <i>et al.</i> , "New Techniques in Stereotaxic Surgery and Anesthesia in the Mouse," <i>Pharmacol. Biochem. Behav.</i> 63:313-318, Elsevier Science Inc. (1999)   |                |
|                                 | NPL67                 | Mi, S., <i>et al.</i> , "LINGO-1 antagonist promotes spinal cord remyelination and axonal integrity in MOG-induced experimental autoimmune encephalomyelitis," <i>Nat. Med.</i> 13:1228-1233, Nature Publishing Group (October 2007)   |                |
|                                 | NPL68                 | Morell, P., <i>et al.</i> , "Gene Expression in Brain during Cuprizone-Induced Demyelination and Remyelination," <i>Molec. Cell. Neurosci.</i> 12:220-227, Academic Press (1998)   |                |
|                                 | NPL69                 | Nagy, P., <i>et al.</i> , "Lipid rafts and the local density of ErbB proteins influence the biological role of homo- and heteroassociations of ErbB2," <i>J. Cell Sci.</i> 115:4251-4262, The Company of Biologists Ltd. (2002)  |                |
|                                 | NPL70                 | Nagy, Z.A., <i>et al.</i> , "Fully human, HLA-DR-specific monoclonal antibodies efficiently induce programmed death of malignant lymphoid cells," <i>Nat. Med.</i> 8:801-807, Nature Publishing Group (2002)   |                |
|                                 | NPL71                 | Orlandi, R., <i>et al.</i> , "Cloning immunoglobulin variable domains for expression by the polymerase chain reaction," <i>Proc. Natl. Acad. Sci. USA</i> 86:3833-3837, National Academy of Sciences (1989)  |                |
|                                 | NPL72                 | Park, S.-K., <i>et al.</i> , "The erbB2 gene is required for the development of terminally differentiated spinal cord oligodendrocytes," <i>J. Cell Biol.</i> 154:1245-1258, The Rockefeller University Press (2001)   |                |

|                    |                 |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
|--------------------|-----------------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|  |   |    |   |                          |  |
|--|---|----|---|--------------------------|--|
| <b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><i>(Use as many sheets as necessary)</i> |   |    |   | <b>Complete if Known</b> |  |
|  |   |    |   | Application Number       | 10/553,685 ( <i>Natl. Phase of PCT/US2004/008323</i> ) |
|  |   |    |   | Filing Date              | §371 Date: November 1, 2006                            |
|  |   |    |   | First Named Inventor     | MI, Sha  |
|  |   |    |   | Art Unit                 | 1656   |
|  |   |    |   | Examiner Name            | CARLSON, Karen C.                                      |
| Sheet  | 5 | of | 7 | Attorney Docket Number   | 2159.0440003/EJH/CLD                                   |

| NON PATENT LITERATURE DOCUMENTS |                       |   |                 |
|---------------------------------|-----------------------|---|-----------------|
| Examiner Initials*              | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published                                   | T <sup>2</sup>  |
|                                 | NPL73                 | Park, J.B., <i>et al.</i> , A TNF Receptor Family Member, TROY, is a Coreceptor with Nogo Receptor in Mediating the Inhibitory Activity of Myelin Inhibitors," Erratum in <i>Neuron</i> 3:815, Elsevier Inc. (March 2005)   |                 |
|                                 | NPL74                 | Pinkas-Kramarski, R., <i>et al.</i> , "Neu Differentiation Factor/Neuregulin Isoforms Activate Distinct Receptor Combinations," <i>J. Biol. Chem.</i> 271:19029-19032, The American Society for Biochemistry and Molecular Biology, Inc. (1996)   |                 |
|                                 | NPL75                 | Plant, G.W., <i>et al.</i> , "Purified Adult Ensheathing Glia Fail to Myelinate Axons under Culture Conditions that Enable Schwann Cells to Form Myelin," <i>J. Neurosci.</i> 22:6083-6091, Society for Neuroscience (2002)   |                 |
|                                 | NPL76                 | Qiu, X.-B. and Goldberg, A.L., "Nrdp1/FLRF is a ubiquitin ligase promoting ubiquitination and degradation of the epidermal growth factor receptor family member, ErbB3," <i>Proc. Natl. Acad. Sci. USA</i> 99:14843-14848, National Academy of Sciences (2002)                          |                 |
|                                 | NPL77                 | Rauchenberger, R., <i>et al.</i> , "Human Combinatorial Fab Library Yielding Specific and Functional Antibodies against the Human Fibroblast Growth Factor Receptor 3," <i>J. Biol. Chem.</i> 278:38194-38205, The American Society for Biochemistry and Molecular Biology, Inc. (2003) |                 |
|                                 | NPL78                 | Rubinson, D.A., <i>et al.</i> , "A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference," <i>Nat. Genet.</i> 33:401-406, Nature Publishing Group (2003)   |                 |
|                                 | NPL79                 | Schmucker, J., <i>et al.</i> , "erbB3 Is Dispensable for Oligodendrocyte Development <i>In Vitro</i> and <i>In Vivo</i> ," <i>Glia</i> 44:67-75, Wiley-Liss, Inc. (2003)  |                 |
|                                 | NPL80                 | Shah, B.H., <i>et al.</i> , "Role of EGF Receptor Transactivation in Phosphoinositide 3-Kinase-Dependent Activation of MAP Kinase by GPCRs," <i>J. Cell. Physiol.</i> 206:47-57, Wiley-Liss Inc. (January 2006)   |                 |
|                                 | NPL81                 | Stolt, C.C., <i>et al.</i> , "Terminal differentiation of myelin-forming oligodendrocytes depends on the transcription factor Sox10," <i>Genes &amp; Dev.</i> 16:165-170, Cold Spring Harbor Laboratory Press (2002)  |                 |
|                                 | NPL82                 | Sussman, C.R., <i>et al.</i> , "The ErbB4 Neurogulin Receptor Mediates Suppression of Oligodendrocyte Maturation," <i>J. Neurosci.</i> 25:5757-5762, Society for Neuroscience (June 2005)   |                 |
| Examiner Signature              |                       |   | Date Considered |

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|  |   |    |   |                          |  |
|--|---|----|---|--------------------------|--|
| Substitute for form 1449/PTO<br><br><b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><i>(Use as many sheets as necessary)</i> |   |    |   | <b>Complete if Known</b> |  |
|  |   |    |   | Application Number       | 10/553,685 ( <i>Natl. Phase of PCT/US2004/008323</i> ) |
|  |   |    |   | Filing Date              | §371 Date: November 1, 2006                            |
|  |   |    |   | First Named Inventor     | MI, Sha  |
|  |   |    |   | Art Unit                 | 1656   |
|  |   |    |   | Examiner Name            | CARLSON, Karen C.                                      |
| Sheet  | 6 | of | 7 | Attorney Docket Number   | 2159.0440003/EJH/CLD                                   |

| NON PATENT LITERATURE DOCUMENTS |                       |   |                |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials*              | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published | T <sup>2</sup> |
|                                 | NPL83                 | Trapp, B.D., <i>et al.</i> , "Pathogenesis of tissue injury in MS lesions," <i>J. Neuroimmunol.</i> 98:49-56, Elsevier Science B.V. (1999)  |                |
|                                 | NPL84                 | Trapp, B.D., <i>et al.</i> , "Axonal pathology in multiple sclerosis: relationship to neurologic disability," <i>Curr. Opin. Neurol.</i> 12:295-302, Lippincott Williams & Wilkins (1999)   |                |
|                                 | NPL85                 | Tzahar, E., <i>et al.</i> , "Bivalence of EGF-like ligands drives the ErbB signaling network," <i>EMBO J.</i> 16:4938-4950, Oxford University Press (1997)  |                |
|                                 | NPL86                 | Vartanian, T., <i>et al.</i> , "Failure of spinal cord oligodendrocyte development in mice lacking neuregulin," <i>Proc. Natl. Acad. Sci. USA</i> 96:731-735, National Academy of Sciences (1999)   |                |
|                                 | NPL87                 | Williams, E.-J. and Doherty, P., "Evidence for and against a Pivotal Role of PI 3-Kinase in a Neuronal Cell Survival Pathway," <i>Molec. Cell. Neurosci.</i> 13:272-280, Academic Press (1999)  |                |
|                                 | NPL88                 | Xu, W., <i>et al.</i> , "Chaperone-dependent E3 ubiquitin ligase CHIP mediates a degradative pathway for c-ErbB2/Neu," <i>Proc. Natl. Acad. Sci. USA</i> 99:12847-12852, National Academy of Sciences (2002)  |                |
|                                 | NPL89                 | Yang, L., <i>et al.</i> , "A novel azulenyl nitron antioxidant protects against MPTP and 3-nitropropionic acid neurotoxicities," <i>Exp. Neurol.</i> 191:86-93, Elsevier Inc. (January 2005)  |                |
|                                 | NPL90                 | Zhou, P., <i>et al.</i> , "ErbB2 Degradation Mediated by the Co-chaperone Protein CHIP," <i>J. Biol. Chem.</i> 278:13829-13837, The American Society for Biochemistry and Molecular Biology, Inc. (2003)  |                |
|                                 | NPL91                 | NCBI Entrez, Accession No. AY324322, (first available May 4, 2004; last updated May 4, 2004)  |                |
|                                 | NPL92                 | International Search Report for International Application No. PCT/US2004/008323, mailed on October 15, 2004, European Patent Office, Rijswijk, Netherlands  |                |

|                    |  |                 |  |
|--------------------|--|-----------------|--|
| Examiner Signature |  | Date Considered |  |
|--------------------|--|-----------------|--|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|  |   |    |   |                          |  |
|--|---|----|---|--------------------------|--|
| Substitute for form 1449/PTO<br><br><b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><i>(Use as many sheets as necessary)</i> |   |    |   | <b>Complete if Known</b> |  |
|  |   |    |   | Application Number       | 10/553,685 ( <i>Natl. Phase of PCT/US2004/008323</i> ) |
|  |   |    |   | Filing Date              | §371 Date: November 1, 2006                            |
|  |   |    |   | First Named Inventor     | MI, Sha  |
|  |   |    |   | Art Unit                 | 1656   |
|  |   |    |   | Examiner Name            | CARLSON, Karen C.                                      |
|  |   |    |   | Attorney Docket Number   | 2159.0440003/EJH/CLD                                   |
| Sheet  | 7 | of | 7 |                          |  |

| NON PATENT LITERATURE DOCUMENTS |                       |   |                |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials*              | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published | T <sup>2</sup> |
|                                 | NPL93                 | United States Patent Application No. 11/892,036, inventors Mi, <i>et al.</i> , continuation of PCT/US2006/026271, international filing date of July 7, 2006 (NOT PUBLISHED)   |                |
|                                 | NPL94                 | United States Patent Application No. 12/092,662, inventors Mi, <i>et al.</i> , National Phase of PCT/US2006/042990, international filing date of November 3, 2006 (NOT PUBLISHED)   |                |
|                                 | NPL95                 | United States Patent Application No. 12/095,857, inventors Mi, <i>et al.</i> , National Phase of PCT/US2006/045993, international filing date of December 1, 2006 (NOT PUBLISHED)   |                |
|                                 |                       |   |                |
|                                 |                       |   |                |
|                                 |                       |   |                |
|                                 |                       |   |                |
|                                 |                       |   |                |
|                                 |                       |   |                |
|                                 |                       |   |                |

847113v1

|                    |  |                 |  |
|--------------------|--|-----------------|--|
| Examiner Signature |  | Date Considered |  |
|--------------------|--|-----------------|--|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.